Ipamorelin 10mg — Research Grade Peptide

Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release[1]. Given its high level of specificity, ipamorelin has been of interest in research both as a therapeutic in and of itself as well as a model peptide for understanding how selectivity in receptor binding is achieved.

Glucocorticoids, the class of corticosteroids commonly used to treat inflammation in conditions ranging from cancer to autoimmune disease, have a host of serious side effects that often limit their usefulness. Mitigating the side effects of glucocorticoids could provide for higher dosing of these medications and allow people to remain on them for longer periods of time, both of which could have positive benefits on morbidity and mortality. Ipamorelin has been shown, in several studies, to reduce or even reverse the side effects of glucocorticoid use.

One of the most profound problems associated with long-term glucocorticoid use is loss of bone density and subsequent risk of fracture. Current therapies include bisphosphonates, hormone therapies, and new monoclonal antibodies. All of these are effective treatments in their own rights, but they also all have side effects, limited efficacy, or high cost. Ipamorelin, on the other hand, is relatively inexpensive to produce and has a very limited number of side effects.

Studies in rats indicate that ipamorelin can completely stop bone loss due to corticosteroids and even leads to a four-fold increase in bone formation in rats exposed to these drugs[2]. Further studies indicate that ipamorelin also increases bone mineral density systemically, thereby increasing the strength of both existing bone and newly formed bone[3]. As an added bonus, ipamorelin helps to offset some of the other side effects of steroids, such as muscle wasting and increased visceral fat deposition.

There is evidence to suggest that GH and growth hormone secretagogues like ipamorelin may reduce the catabolic effects that glucocorticoids have on muscle. Research in rats given glucocorticoids shows a decrease in nitrogen wasting in the liver and improved nitrogen balance following administration of ipamorelin[4]. Muscle wasting is one of the primary side effects associated with glucocorticoid use and a common treatment-limiting side effect. The ability to counteract muscle catabolism and bone-density loss with a single drug could be hugely beneficial to patients who require glucocorticoids.

Research in diabetic rats has revealed that ipamorelin can potentiate insulin release. This effect is most likely a result of indirect stimulation of the calcium channel found on pancreatic islet cells where insulin is made and stored[5]. Ipamorelin's actions on the pancreas may help us better understand the functional limitations of type 2 diabetes and lead to the development of novel therapeutics or even preventative measures.

Post-operative ileus (POI) is a common condition that follows certain types of surgery, but is particularly common following abdominal surgery. The condition is characterized by an inability of individuals to take oral nutrition because the GI system ceases to function. It can be characterized by pain, but the primary problem with POI is that it slows discharge from the hospital and lengthens overall recovery time.

Ipamorelin has been investigated in several proof-of-concept clinical trials to determine if administration of the peptide can reduce POI. The research suggests that ipamorelin does shorten time to first meal by approximately 12 hours[6], [7].

Ipamorelin is a selective ghrelin receptor agonist and binds strongly to the ghrelin receptor. The ghrelin receptor is known to increase in abundance in certain types of cancer (e.g. human carcinomas) and heart failure. Given these facts, researchers recently speculated that ipamorelin could be used as a probe in positron emission tomography (PET) as an aid to diagnosis.

Basic in vitro studies have demonstrated the feasibility of this approach and have confirmed that ipamorelin[8], which is easy to synthesize in a lab, could theoretically be used as a PET probe.